Bristol Myers Squibb vs Teva Pharmaceuticals
Add, change or remove companies; up to four.
The short version
- Bristol Myers Squibb is the larger business, with $48.2B of revenue in fiscal 2025 against $17.3B for Teva Pharmaceuticals, about 2.8 times as much.
- Teva Pharmaceuticals grew revenue faster (4.3%, against −0.2%).
- Bristol Myers Squibb turned more of its sales into free cash flow (26.7% FCF margin, against 6.7%).
- Bristol Myers Squibb earned a higher return on the capital invested in it (15.2%, against 10.5%).
- Investors pay more for each dollar of Teva Pharmaceuticals’s earnings: a P/E of 65.7x against 13.5x for Bristol Myers Squibb.
| Latest fiscal year | BMY · FY25 | TEVA · FY25 |
|---|---|---|
| Size | ||
| Market cap | $125.9B | $45.9B |
| Revenue | $48.2B | $17.3B |
| Free cash flow | $12.8B | $1.1B |
| Net income | $7.1B | $1.4B |
| Growth | ||
| Revenue growth | −0.2% | 4.3% |
| 5-year growth | 2.5% | 0.7% |
| Share count change | 0.6% | 2.8% |
| Profitability | ||
| Gross margin | 71.1% | 51.8% |
| Operating margin | — | 12.5% |
| Net margin | 14.6% | 8.2% |
| FCF margin | 26.7% | 6.7% |
| Return on capital | 15.2% | 10.5% |
| Return on equity | 40.5% | 21.2% |
| Balance sheet | ||
| Net debt | $36.4B | $13.3B |
| Net debt / EBITDA | 2.4x | 4.2x |
| Dividends and buybacks | $5.0B | $0.0M |
| Valuation & quality | ||
| P/E | 13.5x | 65.7x |
| Piotroski F-score | 8 | 8 |
Revenue
FY16
BMY $19.4B
TEVA $21.9B
FY17
BMY $20.8B
TEVA $21.9B
FY18
BMY $22.6B
TEVA $18.3B
FY19
BMY $26.1B
TEVA $16.9B
FY20
BMY $42.5B
TEVA $16.7B
FY21
BMY $46.4B
TEVA $15.9B
FY22
BMY $46.2B
TEVA $14.9B
FY23
BMY $45.0B
TEVA $15.8B
FY24
BMY $48.3B
TEVA $16.5B
FY25
BMY $48.2B
TEVA $17.3B
BMY
TEVA
Operating margin
FY16
BMY —
TEVA 9.8%
FY17
BMY —
TEVA −80.0%
FY18
BMY —
TEVA −9.0%
FY19
BMY —
TEVA −2.6%
FY20
BMY —
TEVA −21.4%
FY21
BMY —
TEVA 10.8%
FY22
BMY —
TEVA −14.7%
FY23
BMY —
TEVA 2.7%
FY24
BMY —
TEVA −1.8%
FY25
BMY —
TEVA 12.5%
BMY
TEVA
Free cash flow
FY16
BMY $1.8B
TEVA $3.0B
FY17
BMY $4.2B
TEVA $1.4B
FY18
BMY $6.1B
TEVA $1.8B
FY19
BMY $7.4B
TEVA $223M
FY20
BMY $13.3B
TEVA $638M
FY21
BMY $15.2B
TEVA $236M
FY22
BMY $11.9B
TEVA $1.0B
FY23
BMY $12.7B
TEVA $842M
FY24
BMY $13.9B
TEVA $749M
FY25
BMY $12.8B
TEVA $1.1B
BMY
TEVA
Return on capital
FY16
BMY 27.7%
TEVA 2.1%
FY17
BMY 18.0%
TEVA −23.0%
FY18
BMY 37.8%
TEVA −2.8%
FY19
BMY 7.9%
TEVA −0.8%
FY20
BMY −5.4%
TEVA −7.5%
FY21
BMY 11.4%
TEVA 3.5%
FY22
BMY 11.0%
TEVA −5.9%
FY23
BMY 14.7%
TEVA 1.3%
FY24
BMY −8.7%
TEVA −1.1%
FY25
BMY 15.2%
TEVA 10.5%
BMY
TEVA
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.